AC Immune Posts Positive Phase 2 Parkinson’s Data, Starts Phase 1 NLRP3 Trial
AC Immune’s wholly-owned ACI-7104 generated positive interim Phase 2 VacSYn results showing slowed Parkinson’s progression with 100% immune response and no safety issues, with final Part 1 data expected mid-2026. The company also dosed first participants in its ACI-19764 NLRP3 inhibitor Phase 1 trial and holds CHF 91.4 million cash.
1. Positive Interim Phase 2 VacSYn Results
In Part 1 of the Phase 2 VacSYn trial, ACI-7104 achieved its immunogenicity, pharmacodynamic and target engagement goals in early Parkinson’s patients, with a 100% responder rate and no clinically relevant safety concerns. Interim data suggest the active immunotherapy may slow disease progression, with full 24-month results due mid-2026.
2. Phase 1 Trial of ACI-19764 Initiated
AC Immune has dosed the first participants in a Phase 1 study of ACI-19764, a brain-penetrant NLRP3 inflammasome inhibitor. This small molecule targets neuroinflammation in Parkinson’s, Alzheimer’s, ALS and other conditions, and could extend to inflammatory and metabolic disorders beyond neurodegeneration.
3. Cash Runway Extended and Upcoming Milestones
The company reported CHF 91.4 million in cash as of December 31, 2025, sufficient to fund operations through Q3 2027. Following a 30% workforce reduction, focus is on key programs with upcoming milestones including ACI-7104 final Part 1 data mid-2026, ACI-24 interim AD data H1 2026 and ACI-19764 Phase 1 results in H2 2026.